Quovadx Inc

Quovadx — Carescience — Merger or Acquisition (August 2003)

29 slides from Quovadx's merger presentation, Aug 14, 2003

  1. Slide 1: Web Services Anywhere

    Web Services Anywhere Access Any Data Perform Any Process From Anywhere...

  2. Slide 2: Additional Information Regarding the CareScience Acquisition

    Additional Information Regarding the CareScience Acquisition In this presentation we will be discussing Quovadx's proposed anticipated acquisition of CareScience, Inc. Quovadx intends to commence an exchange offer for the outstanding shares of CareScience and to file with the Securities and Exchange

  3. Slide 3: Forward-Looking Statements

    Forward-Looking Statements Certain statements in this presentation are "forward-looking statements" within the meaning of the the Private Securities Litigation Reform Act of 1995, including statements regarding the timing and expected completion of the CareScience acquisition, the anticipated effect

  4. Slide 4: Quovadx Announces Acquisition of CareScience

    Quovadx Announces Acquisition of CareScience - Extends Leadership in the Healthcare Industry QVDX: Trailing Twelve Months Revenue: $67.4M CARE: Trailing Twelve Months Revenue: $13.5M

  5. Slide 5: CareScience Acquisition

    CareScience Acquisition $28 Million Transaction (Includes Approximately $14 Million Acquired Cash) $1.40 Cash per Share ($18.6 Million) 0.1818 Share QVDX per CARE share 2.4 Million new QVDX shares to be issued Transaction, Net of Cash, Valued at 1X Trailing Twelve Months Revenue Highly Visible, High

  6. Slide 6: CareScience at a Glance

    CareScience at a Glance Trailing 12 Months: Revenue: $13.5 Million Gross Profit: $ 6.7 Million Gross Margin: 50% R & D: $4.1 Million SG&A: $9.2 Million Balance Sheet at 6.30.03: Cash & Investments: $14.6 Million $0.3 Million Debt Working Capital: $10.7 Million Revenue Backlog at 6.30.03: $33.2 Milli

  7. Slide 7: CareScience Offerings

    CareScience Offerings Solutions Provider to Hospitals and Healthcare Systems Care Management System for Quality Measurement and Care Management Care Data Exchange for Cross-enterprise Data Sharing and Patient-centric Data Access Care Management Services Ranging from Consulting and Facilitation to Ca

  8. Slide 8: Identified Synergies

    Identified Synergies Revenue Opportunity Cross-Sell CareScience Products to 1700 Quovadx Health Care Customers Offer QUOVADX(tm) Technology to CareScience Customers Cost Reduction Opportunity Elimination of Public Company Costs Data Center Consolidation R & D Synergies Absorption of General and Admi

  9. Slide 9: CareScience Strategic Fit

    CareScience Strategic Fit CARE Offers: Deep Care Management and Clinical Process Improvement Expertise Industry-leading Care Process Analysis Technology Over 170 Hospital Customers in 34 States Highly Visible, High Margin, Recurring Revenue Model with Significant Backlog QVDX Offers: Integration Pla

  10. Slide 10: Quovadx Creates Competitive Process Advantage

    Quovadx Creates Competitive Process Advantage

  11. Slide 11: Company Profile

    Company Profile 450 professionals in nine U.S. offices and one in the U.K

  12. Slide 12: Quovadx Customers - 3500+

    Quovadx Customers - 3500+ ee e@: ING cy @ *erre mm gq one 2 powones ee McGraw-Hill “ . 1 Drover gor gy MORN LET ee ZURICH erence F XN & P&OWA Cruises eo LLOYD'S _nieisen HCA & Besioh Myers Squibb Company STANDARD TransUnion. oe VIACOM. ExenMobil

  13. Slide 13: Company phases of growth

    PHASE | XML Services &}xcarenet. + Portal Design and Construction + Architacture for Composite Application Development Rs es 8 8 se + Early Workin XMLand Topic Navigation Mapping 2 REVENUE IN MILLIONS > S QUOVADX Building *S17M Venture Round +si04M 1P0 + XTiera Platform aoe = PHASE Il PHASE IV Acqui

  14. Slide 14: Market Opportunity

    Market Opportunity Two Major Market Segments Worldwide Application Integration Spending $5 billion in 2000; $9 billion in 2005 Global Healthcare IT spending $69 billion in 2002; $103 billion in 2006 Quovadx Emphasizes Key Customer Priorities Providers Clinical Quality, Reimbursement Improvement, Fac

  15. Slide 15: Focus on Strategic Sectors

    Focus on Strategic Sectors | APPLICATION DEVELOPMENT TOOLS INTEGRATION SERVICES Provider ra Aehiormnanas ‘Medical Management «Cash Accteatar *oustomerfonus “INSURENET *hanaged Cre “HIPAA Excess THonsacion Manager Sang Parmer ating Pare doa Managorant *Physcan Porta *PhoenalASP Oferng) _”'sigenty Man

  16. Slide 16: Leading the Way in Web Services

    Leading the Way in Web Services Quovadx Core Competency is XML Tremendous Advantage Avoid Translation, Complexity, etc. WS-I Leadership - Demonstrating Supply Chain Application on WS-I Test Site Major Advantage to Healthcare Organizations Reuse of Laboratory and Radiology Results

  17. Slide 17: Software License Fee Multiplier

    Software License Fee Multiplier

  18. Slide 18: Vendor Comparison

    mee Vendor Comparison QUOVADX nx Ptadsonv pron Seen ejenaor Adaptive hyplicoons (OK doy Manserert anxcusumefect TaINSURENET® Seon (0X Payer Soa Suite DK uiporate Acton Menogemere XCalabome Monae (Ux octane Spper Sons LARK CCK w VA Mens: eure FATIBCO OVITRIA wtnieote —29o0 va W ¢ ¥ « Y ¢ ¢ «

  19. Slide 19: Quarterly License Revenue - Sequential Growth

    Quarterly License Revenue - Sequential Growth

  20. Slide 20: Market Share No Clear Winners

    Market Share No Clear Winners

  21. Slide 21: Quarterly License Revenue

    Quarterly License Revenue License Rev. As % of Total 11% 18% 24% 31% 38%

  22. Slide 22: Revenue Mix

    Revenue Mix 6 Months 2003 Other Rocuring

  23. Slide 23: Target Operating Model

    eae | arget Operating Model Percent of Target Revenue Revenue Margin License 50% 85% - 90% Services 20% 45% - 50% Recurring 30% 45% - 50% Gross Margin 65% - 70% Operating expenses: Sales and Marketing ~22% General and Administrative ~13% Research and Development ~10% Total operating expenses. ~A5N O

  24. Slide 24: Margin Comparisons: 2Q03 vs 1Q03

    Margin Comparisons: 2Q03 vs 1Q03

  25. Slide 25: 2Q03 vs. 1Q03 GAAP Results

    2Q03 vs. 1Q03 GAAP Results Gross margin Selling and marketing General & administrative Research and development Amortization of acquired intangibles Total costs and expenses Operating earnings (loss) Interest income, net Net income (loss) Earnings (loss) per share (basic and diluted) Weighted averag

  26. Slide 26: Balance Sheet Highlights

    ma Balance Sheet Highlights (in Thousands, except per share and DSO) 6730/2003 _3/3112003 Cash, cash equivalents and short-term investments $ 42091 $ 44,909 Per share $138 $149 Accounts receivable $ 16,799 $ 18,984 so 78 96 Nate Receivable $ 2318 $ 2,643 Working capital $ 48,767 $ 49,507 Total asset

  27. Slide 27: Cash Usage

    eee 2 Cash Usage Review of Second Quarter Cash Usage (In Thousands) ‘Cash’ Earnings $ 1,947 Cash Used in Operating Activities Decrease in Receivables 2,054 Decrease in Payables & Accrued Liab: (2,856) Decrease in Uneamed Revenues (3,262) Decrease in Other Assets 157 Net Cash Used in Operating Activi

  28. Slide 28: QVDX - An Attractive Investment

    QVDX - An Attractive Investment Growth Strategies Pursue Web Services Extend Business Model to New Markets Further Develop Partner and Distributor Alliances Investment Appeal Operate in Large, Growing Market Offer Attractive ROI for Customers Highly Leveraged Model Solid Balance Sheet, No Debt

  29. Slide 29: Web Services Anywhere

    Web Services Anywhere Access Any Data Perform Any Process From Anywhere...

Carescience — Merger or Acquisition (August 2003) on 6ix